Poster: IBCL-117 ASPEN: Long-Term Follow-Up Results of a Phase 3 Randomized Trial of Zanubrutinib vs Ibrutinib in Patients With Waldenström Macroglobulinemia

Jorge J. Castillo,Constantine S. Tam,Ramon Garcia-Sanz,Stephen Opat,Shirley D'Sa,Wojciech Jurczak,Hui-Peng Lee,Gavin Cull,Roger G. Owen,Paula Marlton,Bjorn E. Wahlin,Alessandra Tedeschi,Tanya Siddiqi,Christian Buske,Veronique Leblond,Wai Y. Chan,Jingjing Schneider,Aileen Cohen,Meletios Dimopoulos

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览3

暂无评分

摘要

ASPEN is the largest phase 3 WM trial with head-to-head BTKi comparison. At a median follow-up of 43 months, zanubrutinib had higher CR+VGPR rates and clinically meaningful advantages in long-term safety/tolerability versus ibrutinib.

查看译文

关键词

IBCL,Waldenström macroglobulinemia,BTK inhibitor,zanubrutinib,ASPEN,Phase III

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要